

FluoGuide A/S invites investors to Q3 webcast - Clinical progress and the road ahead

FluoGuide A/S will publish its interim report for Q3 2026 on Thursday, 26 November 2026, followed by a live investor webcast later the same day at 14:00 CET.

CEO Morten Albrechtsen and CFO Ole Larsen will

- present the company's operational and financial results
- provide an update on key clinical developments, including the US pivotal trial of FG001 in high-grade glioma
- present upcoming milestones

The webcast will be hosted and moderated by Cecilia Hallström from BioStock and will include a live Q&A session, offering investors the opportunity to ask questions directly to the management.

Questions can be asked during the event or submitted in advance by e-mail to redaktion@biostock.se.

Date: Thursday 26 November 2026

Time: 14.00 CET

Please login to the webcast via the following link: <https://biostock.se/en/2026/10/fluoguide-comments-on-q3/>

A recorded version of the presentation will be available on FluoGuide's website after the webcast.

For further information, please contact:

Morten Albrechtsen, CEO

FluoGuide A/S

Phone: +45 24 25 62 66

E-mail: ma@fluoguide.com

Follow FluoGuide on LinkedIn

Follow FluoGuide on LinkedIn: <https://www.linkedin.com/company/fluoguide/>

Sign up to receive FluoGuide news

Sign up to receive FluoGuide news: <https://fluoguide.com/investor/email-alerts/>



PRESS RELEASE

23 October 2026 10:00:00 CEST

Attachments

[FluoGuide A/S invites investors to Q3 webcast - Clinical progress and the road ahead](#)